Six-month report - 2000

Six-month report 2000 * The operation series in the first randomized multicenter study with injured anterior crutiate ligament (ACL) has been finalized. EU certification is expected to take place during Q4 2000. A second multicenter study has been initiated in Finland and expanded in Sweden. * Preparatory work for market launch of the first ligament product continues. Michael Nordh from AstraZeneca has been recruited with responsibility for the build-up of Artimplant's global market organization. Artimplant expects to launch several products during the next two year period. * At an international hand surgery congress in Kuopio, Finland, short term follow-up results were presented on treatment of chronic thumb ligament injuries where Artimplant's augmentation ligament has been used. All five patients included in a pilot study had after six months regained normal joint stability and grasp strength in the operated joint. * The build-up of full scale production is ongoing and is expected to be completed during the second half of 2000. * In addition to earlier approved patents, the company received one additional patent approval during the second quarter. Artimplant plans to file further patent applications during 2000. * Artimplant Drug Delivery Systems AB, a wholly-owned subsidiary for the development and commercialization of Artimplant's carrier technology within the drug delivery area, is being incorporated. * A directed share issue, whereof the main share was subscribed by international institutional investors, provided the company with net proceeds of SEK 136m during the second quarter. * All employees and persons tied to the Artimplant Group were offered to participate in a warrant program whereof approximately 75 per cent chose to subscribe. Of persons in management position or with specialist competence, 28 of 30 chose to subscribe. In total 243,100 rights were subscribed. * Revenues for the Group during the first six months amounted to SEK 12.4m (10.0m). The operating result amounted to SEK -10.1m (-5.0m). Result after financial items amounted to SEK -6.1m (-4.6m). Earnings per share after taxes amounted to SEK -0.74 (SEK -0.70). ------------------------------------------------------------ This information was brought to you by BIT The following files are available for download: The full report The full report

About Us

Artimplant is a research- and development company, active within bio-materials.